News
NEWS
-
R&DCore patents for albumin-free, serum-free HSC expansion method allowed in Japan
-
newsJoining the 2025 AABB/Cord Blood Connect in San Diego
-
financing
Celaid Therapeutics Raises JPY 1.055 Billion (USD 7.2 Million) in the First Close of its Series B Financing
-
HRCareer Opportunities
-
newsExhibit at BioJapan 2025
-
newsParticipate in the 2025 Cell & Gene Meeting on the Mesa
-
newsExhibiting at Global Startup EXPO 2025
-
R&D
Successful Completion of AMED Stage-Gate Evaluation for CLD-001 Development Program
-
R&D
Celaid Therapeutics have executed a collaborative research agreement with AGC on Expansion and Functional Evaluation of iPSC-HSPCs